Evernow Review – Brand-Name Only, Paired With HRT

Most of this category sells compounded copies. Evernow lists four FDA-approved brands and nothing else, and pairs them with hormone therapy for women going through menopause. Both choices are defensible and unusual. Neither comes with a price.

Brand-Name Only

The medications listed are Ozempic, Wegovy, Zepbound and Mounjaro — all FDA-approved, all named explicitly, with no compounded option offered.

That distinction matters more since the shortage exception closed — the FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage on 21 February 2025, which changed the basis on which those molecules may be compounded at all. Our compounded versus brand-name guide covers the consequences. A service that never went down the compounded route does not have to navigate any of it.

The trade-off is cost, and it is a big one. Brand-name GLP-1s carry list prices far above compounded alternatives, and without insurance coverage that gap is the difference between a few hundred dollars a month and a great deal more. Which makes the absence of any pricing on the site a more serious omission here than it would be elsewhere.

One detail worth noting: Ozempic and Mounjaro are approved for type 2 diabetes, while Wegovy and Zepbound are the same molecules approved for weight management. Listing all four together is common in this market, but if you do not have diabetes, the weight-management approvals are the relevant ones, and prescribing the diabetes versions for weight loss is an off-label use worth discussing explicitly with the prescriber.

The Menopause Pairing Makes Sense

Evernow’s stated differentiator is combining weight-loss medication with HRT for menopause-related weight gain. This is more than positioning.

The menopausal transition is associated with real changes in body composition — a shift toward central and visceral fat distribution, alongside declines in muscle mass and metabolic rate. Women often describe weight arriving in a different place and behaving differently than before, and that description is not imagined. A service treating the hormonal transition and the weight in the same practice is addressing a coherent clinical picture rather than treating a number in isolation.

Nearly every GLP-1 telehealth service we review would prescribe a woman in her fifties a GLP-1 without ever asking about her menopausal status. That is a real gap, and closing it is the strongest argument for Evernow. It also means one prescriber holds both halves of the picture, which matters when symptoms could belong to either.

We should be careful about how far to take this. HRT is a treatment for menopausal symptoms with its own risk and benefit profile that has to be assessed individually; it is not a weight-loss drug, and Evernow does not claim it is. What the pairing offers is joined-up care, not a multiplier on weight loss.

Insurance for Visits Is Not Insurance for Drugs

The site states it is “now accepting insurance for video visits”, displaying Blue Cross Blue Shield, Anthem, UnitedHealthcare and Aetna.

This is the same structure we flagged at knownwell, where a $31 average insured visit sits alongside an unpublished medication cost. Many commercial plans exclude weight-management medication entirely, and those that cover it frequently require prior authorisation and documented criteria. Insured visits are a genuine benefit; they are not the benefit that decides affordability.

Before booking, establish two separate things: whether your plan covers Evernow’s visits, and whether your plan’s pharmacy benefit covers Wegovy or Zepbound for weight management. Our GLP-1 insurance coverage guide covers how to check the second.

What Is Missing

No pricing appears anywhere — not for consultations, medication or hormone therapy. For a brand-name-only service this is the most consequential gap on the site, since the plausible range of what you might pay is enormous depending on coverage.

There is also no published list of states served, no BMI or eligibility criteria, and no description of laboratory requirements. Hormone therapy prescribing in particular usually involves assessment that the site does not describe.

Provider Facts

Pros and Cons

Who It May Be Best For

A strong fit if you are perimenopausal or menopausal, want your hormone symptoms and your weight handled by the same clinician, and you want FDA-approved medication rather than a compounded copy.

Especially if you have insurance that covers weight-management medication — that is the scenario where brand-name-only becomes the cheapest option rather than the most expensive.

Check your pharmacy benefit first, separately from the visit coverage. If your plan excludes weight-management drugs, a brand-name-only service may cost several times what a compounded competitor charges.

Alternatives

Midi Health and Alloy are the closest menopause comparisons. Measured publishes brand-name prices up front. knownwell bills insurance directly. Our GLP-1 insurance coverage guide covers checking your benefit.

Limitations of This Review

Based on Evernow’s own published materials at evernow.com, checked on 6 September 2026. Anything marked not published means we could not find it on the pages we reached — pricing and state coverage are likely disclosed during the intake quiz or an eligibility check we did not complete. Statements about body composition changes in menopause, GLP-1 approvals and shortage resolution dates come from published clinical and FDA sources, not from Evernow. Nothing here is medical advice, and decisions about hormone therapy in particular require individual assessment by a clinician.

Frequently Asked Questions

Verdict

The point worth carrying beyond this provider: “we accept insurance” is two different claims wearing one sentence. Coverage for the visit and coverage for the medication are decided by different parts of your plan, and only the second one determines whether you can afford to continue.